A scoping review published in Frontiers in Public Health has mapped evidence on inequities in access to lung cancer screening among vulnerable populations across the 28 countries that were members of the European Union at the time of the research. The review, led by researchers at the University of Debrecen in Hungary and affiliated institutions in Italy, found that socioeconomic disadvantage was the factor most consistently associated with poorer access indicators, including lower screening participation, uptake, and invitation uptake.
The review, registered on the Open Science Framework and conducted according to established scoping review methodology, included nine studies published between 2015 and 2024. These comprised primary empirical studies using quantitative, qualitative, or mixed-methods designs, as well as secondary and contextual sources such as review articles and policy analyses. The researchers used the Levesque et al. framework of healthcare access to categorise barriers across five dimensions: approachability, acceptability, availability and accommodation, affordability, and appropriateness.
According to the review, acceptability barriers — factors such as stigma, fear, mistrust of the healthcare system, or cultural beliefs that make individuals less willing to seek or accept screening — were the most frequently reported across the included studies. Additional disparities were observed according to ethnicity, sex, and age, although the findings were not uniform across all groups.
The review highlights that lung cancer remains the leading cause of cancer mortality in the EU, accounting for approximately one-fifth (19.4%) of all cancer fatalities, and the fourth most diagnosed malignancy, representing about 10.7% of all cases. Low-dose computed tomography (LDCT) has been shown to reduce lung cancer mortality in high-risk populations, with trials such as the Dutch–Belgian NELSON trial and the US National Lung Screening Trial (NLST) demonstrating significant mortality reductions. In 2022, the European Commission encouraged Member States to explore the implementation of lung cancer screening, and the European Code Against Cancer recommends organised and sustainable screening programs.
However, the review's authors note that the benefits of screening are not equally distributed. Vulnerable populations — those affected by social, economic, cultural, ethnic, geographic, or health-related disadvantages — face multiple barriers. Within Europe, implementation of lung cancer screening programs remains limited to a small number of countries, with pilot studies such as HUNCHEST in Hungary, HANSE in Germany, and CASCADE in France underway.
The review's findings suggest that differences in screening access reflect both structural and psychosocial factors. The authors argue that equitable implementation is essential during the current rollout of screening programs in Europe, and that reducing inequalities in cancer prevention and early detection is a stated priority under Europe's Beating Cancer Plan, the 2022 Council Recommendation on Cancer Screening, and the European Cancer Inequalities Registry.
For university students across Europe, the findings carry direct relevance. Many students come from diverse socioeconomic and ethnic backgrounds, and those from disadvantaged groups may face additional barriers to accessing preventive health services, including lung cancer screening. The review underscores that as screening programs expand, attention must be paid to ensuring that vulnerable populations — including those with lower income, less education, or from minority ethnic groups — are not left behind. Students studying public health, medicine, or health policy may find the review a useful resource for understanding the structural and psychosocial factors that shape health inequities.
The review's authors note that research on lung cancer screening uptake and barriers among vulnerable populations in the EU remains limited and fragmented. They call for further studies to address this gap, particularly as screening programs are rolled out more broadly across the region.